Please assess the completion status of the following clinical trial:

Trial Title: Effects of Selenium and Melatonin on Ocular Ischemic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patients of Ocular ischemic syndrome (OIS) were the stenosis of the ipsilateral (to the affected eye) internal carotid artery (ICA) was \>50%~* The patients of Ocular ischemic syndrome (OIS) who the ICA blood flow velocity was abnormal;~* Abnormal ocular symptoms and/or signs that could not be explained by other ocular diseases.~Exclusion Criteria:~* The patients who were suffered from other ocular diseases( primary glaucoma, uveitis, age-related macular degeneration, symmetrical proliferative diabetic retinopathy, choroidal detachment, retinal detachment, hereditary eye diseases, ocular tumor, or ocular trauma)

- Gender: ALL
- Minimum Age: 61 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- SELENIUM (Type: OTHER): The patients in this group were supplemented with oral selenium at 0.1mg/kg doses twice daily for one month. After selenium supplementation period was completed, AC sampling as described above.
- MELATONIN (Type: OTHER): The patients in this group were supplemented with oral melatonin 0.5 mg/kg/day doses twice daily for one month. After supplementation was completed 0.1 cc sampling from AC.

Based on this trial design, predict the completion outcome and termination type (if applicable).